NCT03038178View on ClinicalTrials.gov

Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

October 31, 2019

Study Completion Date

December 31, 2019

Conditions
Mycobacterium Infections, NontuberculousMycobacteria, Atypical
Interventions
DRUG

LAI plus multi-drug regimen

Liposomal Amikacin for Inhalation (LAI) is the experimental treatment which, in this single arm will be taken in conjunction with standard of care multi-drug treatment regimen

Trial Locations (2)

75708

University of Texas Health Science Center, Tyler

97239

Oregon Health & Science University, Portland

All Listed Sponsors
collaborator

Insmed Incorporated

INDUSTRY

collaborator

The University of Texas Health Science Center at Tyler

OTHER

lead

Kevin Winthrop

OTHER

NCT03038178 - Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease | Biotech Hunter | Biotech Hunter